Omron turns up home blood pressure monitoring promotion with TV doctor
BANNOCKBURN, Ill. —Omron Healthcare earlier this month joined forces with “The Dr. Oz Show” in an integrated media partnership to help spread the word about the importance of home blood pressure monitoring.
The Omron Healthcare integration included a sponsored segment on “The Dr. Oz Show’s” premiere episode, which aired Sept. 7, in addition to a consumer incentive that was revealed by Dr. Oz during the show. The first 50,000 viewers to visit DoctorOz.com were able to download a $10 coupon good on any Omron Healthcare home blood pressure monitor at participating retailers.
“High blood pressure is a growing concern in the United States among adults, and is often referred to as the ‘silent killer,’” stated Ranndy Kellogg, Omron Healthcare VP marketing and product development. “We’re thrilled to align with ‘America’s Doctor’ in the Sept. 7 season premier to help spread the word about the importance of home blood pressure monitoring, further helping to decrease the risk of heart disease and increase life expectancy.”
As many as 1-in-3 people suffer from high blood pressure, according to the American Heart Association. Monitoring blood pressure at home is an important step people can take to reduce their risk of a heart attack or stroke, Omron stated. More than 50% of people with high blood pressure who monitor at home show an improvement in medication compliance and are quicker to take action.
Pfizer recalls lot of ThermaCare HeatWraps Menstrual
NEW YORK Pfizer’s over-the-counter division recalled one lot of a ThermaCare product over the possibility of leaks.
Pfizer Consumer Healthcare announced Friday the voluntary recall of lot number E06931 of its ThermaCare HeatWraps Menstrual product and notified the Food and Drug Administration.
The company said possible leaks in the wraps could cause skin injury, such as irritation and burning.
AstraZeneca-Bristol drug just as effective as generic on market, trial results show
STOCKHOLM An investigational diabetes drug works as well as a generic already on the market, according to results of a late-stage clinical trial announced Friday by AstraZeneca and Bristol-Myers Squibb.
The two companies said phase-3 trial results showed that their investigational drug dapagliflozin combined with the widely available generic metformin was as effective as glipizide combined with metformin, compared with metformin alone. In addition, patients in the dapagliflozin group experienced weight loss, compared with weight gain in those taking glipizide, as well as a reduced number of patients experiencing abnormally low blood sugar, known as hypoglycemia.
Results from the study were presented at the 46th annual meeting of the European Association for the Study of Diabetes.